Cell Matters acquired by global leader Cryoport

Cell Matters is a CDMO specialized in cryopreservation. The company combines expertise in cryobiology, cell therapy production and bio-logistics. It provides cell therapy companies with cryo-process development or optimization from starting material to Drug Product. The aim of its strategic partnership with Cryoport was to launch a joint service, IntegriCell^TM, to support the development, the optimization, and the actual cryopreservation of leukopaks for cell therapy players requiring timely, high-quality starting material that is manufacturing-ready.

Cryopreservation is a key component of the biomanufacturing supply chain. By joining forces and with GMP expertise, IntegriCell^TM is making cryopreservation a competitive advantage as the demand on the global cell therapy market continues to grow. For Cell Matters, this alliance was the opportunity to accelerate its international expansion. For Cryoport, it offered the opportunity to strengthen its temperature controlled supply chain capabilities in Europe.